{"id":"W4308057391","doi":"10.1182/bloodadvances.2022008216","title":"Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Gilead Sciences; Servier; National Cancer Institute; Regeneron Pharmaceuticals; National Institutes of Health; Sunesis; MacroGenics; Astellas Pharma; Juno Therapeutics; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; Agios Pharmaceuticals; Pharmacyclics; Jazz Pharmaceuticals; PTC Therapeutics; Celgene; Alexion Pharmaceuticals; TG Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Dasatinib; Medicine; Blinatumomab; Prednisone; Minimal residual disease; Internal medicine; Maintenance therapy; Oncology; Chemotherapy; Leukemia; Lymphoblastic Leukemia; Imatinib","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005435595,0.0004183269,0.0007089092,0.0004965775,0.0003758137,0.00004544995,0.0004650216,0.0001525649,0.0006197689],"category_scores_gemma":[0.0003964425,0.0004102536,0.0001613548,0.001552145,0.0002174851,0.0004371198,0.0004140823,0.0008475212,0.00006878102],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002199033,"about_ca_system_score_gemma":0.001538131,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002044147,"about_ca_topic_score_gemma":0.00003218941,"domain_scores_codex":[0.9957386,0.0002321138,0.0007527603,0.0009090898,0.001449719,0.0009177146],"domain_scores_gemma":[0.9982744,0.0004142678,0.0002724795,0.0006194861,0.000115856,0.0003035386],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01020157,0.006969213,0.112833,0.001032775,0.001946912,0.007015811,0.004385664,0.003142979,0.6993829,0.0009985541,0.07356194,0.07852868],"study_design_scores_gemma":[0.2193384,0.02053899,0.05077587,0.001376283,0.003995632,0.0124655,0.0182193,0.03018216,0.283731,0.00392522,0.3495399,0.005911709],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900141,0.002954924,0.0002789359,0.0009257746,0.0006785971,0.001036393,0.0001599146,0.0002369733,0.003714397],"genre_scores_gemma":[0.9917941,0.0004129152,0.001831602,0.0005607184,0.0002758831,0.0006019968,0.0003020723,0.0001014703,0.004119262],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4156519,"threshold_uncertainty_score":0.999835,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01038593191246425,"score_gpt":0.2800741377065346,"score_spread":0.2696882057940704,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}